Sun-Novo(SH:688621) Ge Long Hui A P P·2025-10-19 07:48Core Viewpoint - Sunshine Nuohuo (688621.SH) announced an investment of 15 million yuan to subscribe for an increase in registered capital of Yuanma Zhiyao by 110,556 yuan, resulting in an 8.20% equity stake in the company, which focuses on innovative research and development of circular mRNA CAR-T nucleic acid drugs [1] Group 1 - The investment aims to advance the overall strategic layout in the field of in vivo CAR-T cell therapy and nucleic acid drugs [1] - Yuanma Zhiyao has completed early-stage research on multiple pipelines, including in vivo CAR-T with circular mRNA, and is rapidly progressing towards clinical research [1] - The company is expected to become the first globally to enter clinical trials for modified circular mRNA in vivo CAR-T therapy [1]